Spots Global Cancer Trial Database for radiologic examination

Every month we try and update this database with for radiologic examination cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)	NCT06360575	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Crizotinib Radiologic Exam...	-	National Cancer Institute (NCI)
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)	NCT06360588	Malignant Solid...	Biopsy Biospecimen Col... Copanlisib Radiologic Exam...	-	National Cancer Institute (NCI)
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)	NCT06357975	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Crizotinib Radiologic Exam...	18 Years -	National Cancer Institute (NCI)
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)	NCT06303167	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Echocardiograph... Multigated Acqu... Osimertinib Radiologic Exam...	18 Years -	National Cancer Institute (NCI)
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)	NCT06136897	Malignant Solid...	Biopsy Biospecimen Col... Echocardiograph... Pertuzumab Radiologic Exam... Trastuzumab	18 Years -	National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	NCT02465060	Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ...	Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib	18 Years -	National Cancer Institute (NCI)
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)	NCT06303167	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Echocardiograph... Multigated Acqu... Osimertinib Radiologic Exam...	18 Years -	National Cancer Institute (NCI)
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)	NCT06303167	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Echocardiograph... Multigated Acqu... Osimertinib Radiologic Exam...	18 Years -	National Cancer Institute (NCI)
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)	NCT06360575	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Crizotinib Radiologic Exam...	-	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: